28 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp02972 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 41.21 µM |
| dbacp02973 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 25.20 µM |
| dbacp02974 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 27.00 µM |
| dbacp02975 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 26.70 µM |
| dbacp02976 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 47.69 µM |
| dbacp02977 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 27.39 µM |
| dbacp02978 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 27.39 µM |
| dbacp02986 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 21.48 µM |
| dbacp02987 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 14.53 µM |
| dbacp02988 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.80 µM |
| dbacp02989 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 22.51 µM |
| dbacp02990 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 :29.10 µM |
| dbacp02991 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 :22.25 µM |
| dbacp02992 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 :12.55 µM |
| dbacp03000 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 22.88 µM |
| dbacp03001 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 20.36 µM |
| dbacp03002 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 24.63 µM |
| dbacp03003 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 24.31 µM |
| dbacp03004 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 46.51 µM |
| dbacp03005 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 13.97 µM |
| dbacp03006 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 22.06 µM |
| dbacp03014 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 :22.59 µM |
| dbacp03015 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 15.88 µM |
| dbacp03016 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.80 µM |
| dbacp03017 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 13.77 µM |
| dbacp03018 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 24.32 µM |
| dbacp03019 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 13.16 µM |
| dbacp03020 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 14.58 µM |